Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL957653 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL7779858 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL955673 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL7782669 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL6656018 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL953592 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL956942 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL465609 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL536268 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL835510 | 0.97 | LMNA (0.33) | LMNATHRBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1075461-B1 | PERFLUORINATED ESTERS OF ALKANOYL L-CARNITINE FOR THE PREPARATION OF CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS | SIGMA TAU IND FARMACEUTI (IT) | 2004-07-28 | — | — | EP | claimed |
| US-6476243-B1 | Perfluorinated esters of alkanoyl L-carnitine for the preparation of cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-11-05 | — | — | US | claimed |
| CN-118139839-A | Process for producing fluorinated polyether | 株式会社力森诺科 | 2024-06-04 | — | — | CN | disclosed |
| CN-118055920-A | Process for producing fluorinated polyether | 株式会社力森诺科 | 2024-05-17 | — | — | CN | disclosed |
| US-20220289785-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-09-15 | — | — | US | disclosed |
| US-11117917-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20190153016-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2019-05-23 | — | — | US | disclosed |
| US-10239957-B2 | Peptide containing conjugates for dual molecular delivery of oligonucleotides | MERCK SHARP & DOHME CORP. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10221205-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20190015442-A1 | DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES AND PEPTIDE CONTAINING CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10010562-B2 | Dual molecular delivery of oligonucleotides and peptide containing conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20050192178-A1 | Modified particle, catalyst component for addition polymerization, catalyst for addition polymerization and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | disclosed |
| US-20050148459-A1 | Process for producing modified particle, carrier or catalyst component for addition polymerization, pre-polymerized catalyst component therefor, catalyst therefor, and addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2005-07-07 | — | — | US | disclosed |
| EP-1075461-B1 | PERFLUORINATED ESTERS OF ALKANOYL L-CARNITINE FOR THE PREPARATION OF CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS | SIGMA TAU IND FARMACEUTI (IT) | 2004-07-28 | — | — | EP | disclosed |
| US-6515172-B2 | Oxidation of a perfluoroalkyl iodide | CLARIANT GMBH (DE) | 2003-02-04 | — | — | US | disclosed |
| US-6476243-B1 | Perfluorinated esters of alkanoyl L-carnitine for the preparation of cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-11-05 | — | — | US | disclosed |
| US-20020147357-A1 | Process for the preparation of perfluorocarboxylic acids | CLARIANT GMBH | 2002-10-10 | — | — | US | disclosed |
| EP-1075461-A2 | PERFLUORINATED ESTERS OF ALKANOYL L-CARNITINE FOR THE PREPARATION OF CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999057094-A2 | PERFLUORINATED ESTERS OF ALKANOYL L-CARNITINE FOR THE PREPARATION OF CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-11-11 | — | — | WO | disclosed |
| WO-1987005299-A2 | NEW FLUORINE-CONTAINING SURFACTANTS DERIVED FROM PROTEINIC SUBSTANCES; METHOD FOR OBTAINING THEM AND UTILISATION THEREOF | SZONYI ISTVAN | 1987-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010562-B2 | Dual molecular delivery of oligonucleotides and peptide containing conjugates | DCLRE1A, DCLRE1B, LNPEP | LMNA 872/4885THRB 855/4885CA2 4065/4885 |
| US-20190015442-A1 | DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES AND PEPTIDE CONTAINING CONJUGATES | DCLRE1A, DCLRE1B, LNPEP | LMNA 829/4885THRB 1068/4885CA2 3818/4885 |
| US-20190153016-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | GALNT3, CSGALNACT1, FUT6 | LMNA 1907/4885THRB 254/4885CA2 3281/4885 |
| US-20220289785-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | GALNT3, CSGALNACT1, FUT6 | LMNA 1907/4885THRB 254/4885CA2 3281/4885 |
| US-11117917-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | GALNT3, B3GAT3, CSGALNACT1 | LMNA 1364/4885THRB 268/4885CA2 3282/4885 |
| US-10221205-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | GALNT3, B3GAT3, CSGALNACT1 | LMNA 1364/4885THRB 268/4885CA2 3282/4885 |
| US-10239957-B2 | Peptide containing conjugates for dual molecular delivery of oligonucleotides | AGBL2, LNPEP, DCLRE1B | LMNA 1253/4885THRB 985/4885CA2 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.